<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11314">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584935</url>
  </required_header>
  <id_info>
    <org_study_id>F060213003</org_study_id>
    <nct_id>NCT00584935</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid</brief_title>
  <official_title>Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous
      membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead
      to irreversible damage and blindness. Conventional treatments include systemic steroids,
      dapsone, and immunosuppressive agents. These treatments, however, are not successful with
      all patients. Ritumimab has been very effective in the treatment of other autoimmune
      disorders, and has recently been shown to be effective for autoimmune blistering pemphigus.
      We propose that it will also be effective in the treatment of cicatricial pemphigoid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cicatricial pemphigoid is an autoimmune blistering disease whcih can affect the skin, mucous
      membranes, and, in a small subset of patients, the eyes. Progressive ocular disease can lead
      to irreversible damage and blindness. Conventional treatments have included high dose
      systemic steroids, dapsone, and immunosuppressive agents such as azathioprine, methotrexate,
      cyclophosphamide, and mycophenolate mofetil. However, there are a subgroup of patients who
      fail to respond to these treatments, develop intolerable side effects, or have
      contraindications to their use. Patients may also develop resistance to these conventional
      treatment modalities. For these reasons, alternative treatment modalities are needed.
      Rituximab has been very effective in the treatment of other autoimmune disorders. It has
      recently been shown to be effective in the treatment of another autoimmune blistering
      disorder known as pemphigus. We thus propose that Rituximab will be effective in the
      treatment of cicatricial pemphigoid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stages Characteristics I Subconjunctival scarring and fibrosis II Fornix foreshortening (a-d describes % loss of inferior fornix depth)
0-25%
25-50%
50-75%
75-100% III Presence of symblepharon and number (n) (a-d describes % of horizontal involvement by sympblephara and n is the number of symblephara countable)
a. 0-25% b. 25-50% c. 50-75% d. 75-100% IV Ankyloblepharon, frozen globe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. The Proportion of Patients That Experience a Grade 3, Grade 4, or Grade 5 Toxicity Based Reaction on the NCI-CTC System at the Time of Their Infusions and During Follow-up Visits.</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Stability of Visual Acuity (Snellen's Test) at 16 Weeks</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Stability of Visual Acuity (Snellen's Test) at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Ocular Cicatricial Pemphigoid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of ocular cicatricial pemphigoid (symptoms of conjuctivitis,
             irritation, burning, increased lacrimation, photophobia, dryness of the eyes along
             with conjunctival inflammation, trichiasis, and scarring

          2. One of the following:

               -  Failed response to the use of one or more conventional treatments for a minimum
                  of 10 weeks; or

               -  Minimal conventional medication doses, with a significant adverse effects,
                  contradiction to use, or progressive disease despite treatment

          3. Adults age 19 and older

          4. Adequate renal function as indicated by serum creatinine levels less than 1.5

        Exclusion Criteria:

          1. known hypersensitivity to rituximab or its components

          2. Age less than 19 years

          3. Any other condition deemed by the investigator to be a significant hazard to the
             subject if the investigational therapy were initiated.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig A Elmets</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 5, 2011</lastchanged_date>
  <firstreceived_date>December 26, 2007</firstreceived_date>
  <firstreceived_results_date>February 15, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Craig Elmets, M.D.</name_title>
    <organization>University of Alabama at Birmingham</organization>
  </responsible_party>
  <keyword>Pemphigoid</keyword>
  <keyword>Blistering Diseases</keyword>
  <keyword>Blindness</keyword>
  <keyword>Autoimmune</keyword>
  <keyword>Rituximab</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemphigoid, Benign Mucous Membrane</mesh_term>
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Three patients were recruited from the investigator's practice.</recruitment_details>
      <pre_assignment_details>Subjects must meet inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rituximab</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61" spread="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks</title>
        <description>Stages Characteristics I Subconjunctival scarring and fibrosis II Fornix foreshortening (a-d describes % loss of inferior fornix depth)
0-25%
25-50%
50-75%
75-100% III Presence of symblepharon and number (n) (a-d describes % of horizontal involvement by sympblephara and n is the number of symblephara countable)
a. 0-25% b. 25-50% c. 50-75% d. 75-100% IV Ankyloblepharon, frozen globe</description>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks</title>
            <description>Stages Characteristics I Subconjunctival scarring and fibrosis II Fornix foreshortening (a-d describes % loss of inferior fornix depth)
0-25%
25-50%
50-75%
75-100% III Presence of symblepharon and number (n) (a-d describes % of horizontal involvement by sympblephara and n is the number of symblephara countable)
a. 0-25% b. 25-50% c. 50-75% d. 75-100% IV Ankyloblepharon, frozen globe</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>2. The Proportion of Patients That Experience a Grade 3, Grade 4, or Grade 5 Toxicity Based Reaction on the NCI-CTC System at the Time of Their Infusions and During Follow-up Visits.</title>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1. Stability of Visual Acuity (Snellen's Test) at 16 Weeks</title>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2. Stability of Visual Acuity (Snellen's Test) at 24 Weeks</title>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rituximab</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator is required to submit the final manuscript to the sponsor prior to publication. The sponsor may suggest changes but investigator retains editorial rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Genentech closed trial before site was able to enroll 5 patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wendy Cantrell, CRNP</name_or_title>
      <organization>UAB Department of Dermatology</organization>
      <phone>205-502-9960</phone>
      <email>wcantrell@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
